Hospital
Trinity Health Grand Haven Hospital
Trinity Health Grand Haven Hospital was paid $8.29M by Medicaid between Jan 2018 and Dec 2024, across 183 billing codes. Its largest line is 99284, emergency room visit (serious) — 18% of everything it billed.
33Billing provider infoTRINITY HEALTH GRAND HAVEN HOSPITAL
GRAND HAVEN, MI 49417
GRAND HAVEN, MI 49417
33aNPI1942379284assigned 11/08/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$8.29M
24GClaims251,585
24DCodes billed183
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Michigan
Rank by total paid#67 of 86
Median peer was paid$21.55M
This provider vs. median0.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 25,473 | $626K | |
| 2019 | 23,088 | $592K | |
| 2020 | 25,240 | $712K | |
| 2021 | 40,118 | $1.29M | |
| 2022 | 46,600 | $1.70M | |
| 2023 | 49,753 | $1.78M | |
| 2024incomplete | 41,313 | $1.59M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 18% | 8,161 | 7,784 | $1.49M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 10,111 | 9,486 | $1.19M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.9% | 2,501 | 2,345 | $654K |
| A0427 | Emergency ambulance ride, advanced life supportAmbulance service, advanced life support, emergency transport, level 1 (als 1 - emergency) | 6.6% | 2,533 | 2,328 | $550K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 5.9% | 4,971 | 4,623 | $490K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 4.4% | 3,066 | 3,007 | $367K |
| A0425 | Ground mileage, per statute mile | 3.9% | 5,527 | 4,627 | $323K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 3.8% | 5,330 | 4,674 | $311K |
| A0429 | Emergency ambulance ride, basic life supportAmbulance service, basic life support, emergency transport (bls-emergency) | 3.1% | 1,715 | 1,555 | $259K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.8% | 1,336 | 1,296 | $233K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.6% | 3,228 | 3,143 | $217K |
| 71046 | Radiologic examination, chest; 2 views | 1.9% | 4,087 | 3,962 | $157K |
171 more codes
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.8% | 1,503 | $152K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.7% | 4,144 | $140K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.5% | 3,850 | $125K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 1.5% | 2,021 | $123K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.3% | 3,030 | $106K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.0% | 1,120 | $84K |
| A0428 | Ambulance service, basic life support, non-emergency transport, (bls) | <1% | 520 | $82K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 636 | $59K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 906 | $58K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 491 | $57K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,337 | $55K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 3,023 | $54K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,237 | $52K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 975 | $50K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 2,213 | $44K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,664 | $43K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 632 | $40K |
| 80061 | Lipid panel | <1% | 3,449 | $37K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 5,399 | $36K |
| 58661 | <1% | 12 | $36K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,260 | $36K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,291 | $35K |
| 80053 | Comprehensive metabolic panel | <1% | 14,988 | $33K |
| A0998 | Ambulance response and treatment, no transport | <1% | 202 | $31K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,560 | $30K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 5,742 | $27K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 295 | $25K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 15,836 | $24K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 319 | $21K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,389 | $20K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,384 | $20K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,788 | $18K |
| 36415 | Collection of venous blood by venipuncture | <1% | 22,181 | $18K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 779 | $16K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 333 | $16K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 57 | $15K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 916 | $12K |
| 82947 | <1% | 541 | $11K | |
| 0002A | <1% | 293 | $10K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,120 | $10K |
| 0001A | <1% | 282 | $9K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,054 | $9K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,814 | $9K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 147 | $8K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 349 | $8K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 611 | $7K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,196 | $7K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,146 | $7K |
| 82728 | <1% | 911 | $6K | |
| 87480 | <1% | 640 | $6K | |
| 87660 | <1% | 642 | $6K | |
| 87510 | <1% | 615 | $5K | |
| 82607 | <1% | 722 | $5K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 54 | $5K |
| 86803 | <1% | 634 | $4K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 182 | $4K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 149 | $4K |
| 86900 | <1% | 258 | $3K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,295 | $3K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 914 | $3K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 135 | $3K |
| 81001 | <1% | 9,062 | $3K | |
| 85027 | <1% | 1,046 | $3K | |
| 87186 | <1% | 993 | $3K | |
| 84484 | <1% | 3,294 | $3K | |
| 84439 | <1% | 578 | $3K | |
| 87070 | <1% | 978 | $3K | |
| 87481 | <1% | 106 | $2K | |
| 73630 | <1% | 223 | $2K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 292 | $2K |
| 97162 | <1% | 57 | $2K | |
| 87634 | <1% | 109 | $2K | |
| 83550 | <1% | 455 | $2K | |
| 81025 | <1% | 4,578 | $2K | |
| 83735 | <1% | 2,357 | $2K | |
| 83540 | <1% | 535 | $2K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 38 | $2K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 138 | $2K |
| 87088 | <1% | 593 | $2K | |
| 83690 | <1% | 3,857 | $1K | |
| 97164 | <1% | 55 | $1K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 107 | $1K |
| 0003A | <1% | 35 | $1K | |
| 85610 | <1% | 1,572 | $1K | |
| 85379 | <1% | 1,260 | $962.56 | |
| 83605 | <1% | 1,863 | $932.43 | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 14 | $906.69 |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 63 | $894.83 |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 259 | $868.67 |
| 90686 | <1% | 246 | $820.41 | |
| 86140 | <1% | 497 | $810.73 | |
| 84702 | <1% | 227 | $760.14 | |
| 73562 | <1% | 80 | $723.80 | |
| 93976 | <1% | 14 | $716.17 | |
| 90670 | <1% | 55 | $687.00 | |
| 87147 | <1% | 331 | $667.93 | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 14 | $656.04 |
| 73610 | <1% | 66 | $626.58 | |
| 76830 | Ultrasound, transvaginal | <1% | 12 | $596.40 |
| 76801 | <1% | 12 | $596.40 | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 15 | $564.94 |
| 90791 | Psychiatric diagnostic evaluation | <1% | 12 | $561.05 |
| 97163 | <1% | 14 | $540.07 | |
| 72100 | <1% | 28 | $455.35 | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 24 | $455.00 |
| 82570 | <1% | 158 | $437.50 | |
| 73130 | <1% | 57 | $436.32 | |
| 85651 | <1% | 286 | $406.41 | |
| 74018 | <1% | 41 | $386.64 | |
| 82043 | <1% | 96 | $298.62 | |
| 83880 | <1% | 231 | $288.21 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 24 | $265.61 |
| 96161 | <1% | 45 | $254.00 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 125 | $217.59 |
| Q3014 | Telehealth originating site facility fee | <1% | 15 | $215.10 |
| 87040 | <1% | 160 | $158.78 | |
| 73030 | <1% | 25 | $144.76 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 594 | $144.30 |
| 84100 | <1% | 430 | $128.73 | |
| 82746 | <1% | 16 | $116.21 | |
| 85730 | <1% | 353 | $94.11 | |
| 86901 | <1% | 259 | $77.19 | |
| 86703 | <1% | 14 | $66.38 | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 58 | $57.05 |
| 81003 | <1% | 84 | $49.76 | |
| 87340 | <1% | 16 | $47.95 | |
| 86592 | <1% | 17 | $39.32 | |
| 86850 | <1% | 71 | $34.83 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,893 | $15.00 |
| 84703 | <1% | 152 | $5.74 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 386 | $0.00 |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 922 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 844 | $0.00 |
| 72125 | Computed tomography, cervical spine; without contrast material | 0% | 12 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 77 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 204 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 194 | $0.00 |
| 76376 | 0% | 1,344 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 37 | $0.00 |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | 0% | 109 | $0.00 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 0% | 27 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 42 | $0.00 |
| 91300 | 0% | 306 | $0.00 | |
| 90715 | 0% | 26 | $0.00 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 12 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 57 | $0.00 |
| 90633 | 0% | 12 | $0.00 | |
| 82948 | 0% | 17 | $0.00 | |
| 73110 | 0% | 13 | $0.00 | |
| 88302 | 0% | 24 | $0.00 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 14 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 2,156 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 748 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 589 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 349 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 472 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 179 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 1,961 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 143 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 62 | $0.00 |
| G0378 | Hospital observation service, per hour | 0% | 39 | $0.00 |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 0% | 64 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 435 | $0.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 4,906 | $0.00 |
| 96376 | 0% | 294 | $0.00 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 84 | $0.00 |
| 12001 | 0% | 12 | $0.00 | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 0% | 221 | $0.00 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 0% | 29 | $0.00 |
| 94760 | 0% | 13 | $0.00 | |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFOSS, JOHN (SR VP OPERATIONS)
| Provider | Location | Paid |
|---|---|---|
| Synanon INC | Grand Haven, MI | $600K |
| Noch Physician Billing Company LLC | Grand Haven, MI | $579K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.